FN-1501

Generic Name
FN-1501
Brand Names
Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
Drug Type
Small Molecule
Chemical Formula
C22H25N9O
CAS Number
1429515-59-2
Unique Ingredient Identifier
6MC966B505
Background

Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...

Indication

Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...

Associated Conditions
Transplanted Organ Rejection
Associated Therapies
-
Clinical Trials
Related News
finance.yahoo.com
·

Positive Phase III Results for Genentech's Gazyva Show Superiority to Standard Therapy

Genentech announced positive Phase III REGENCY study results for Gazyva® in active lupus nephritis, showing higher complete renal response rates with Gazyva plus standard therapy compared to standard therapy alone. Gazyva targets disease-causing B cells to prevent progression to end-stage kidney disease.

Related Clinical Trials:

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
globenewswire.com
·

Positive phase III results for Roche's Gazyva/Gazyvaro show

Roche's Gazyva/Gazyvaro showed superior results in treating active lupus nephritis compared to standard therapy alone, achieving a higher complete renal response rate at 76 weeks. The REGENCY study met its primary endpoint, demonstrating significant and clinically meaningful benefits. Gazyva/Gazyvaro targets disease-causing B cells to prevent or delay progression to end-stage kidney disease, a common outcome for up to one-third of lupus nephritis patients within 10 years.

Related Clinical Trials:

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Obinutuzumab in Primary MN
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
biospace.com
·

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Aurinia Pharmaceuticals announces Japanese approval of voclosporin, in combination with mycophenolate mofetil, for treating lupus nephritis, based on the AURORA Clinical Program data.
astrazeneca.com
·

AstraZeneca announces start of recruitment in two new Phase III trials evaluating Saphnelo

Cutaneous lupus erythematosus (CLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), and lupus nephritis (LN) are autoimmune diseases with significant morbidity and unmet medical needs. Phase III trials LAVENDER, JASMINE, IRIS, and DAISY evaluate the efficacy and safety of anifrolumab (Saphnelo), a type I IFN receptor blocker, in treating these conditions. AstraZeneca's Respiratory & Immunology division aims to address chronic, debilitating diseases through innovative medicines.

Related Clinical Trials:

A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
marketscreener.com
·

Ocrevus Zunovo approved by the FDA

Roche is a research-based healthcare company with two divisions: Pharmaceuticals and Diagnostics. Pharmaceuticals include Roche Pharmaceuticals and Chugai, while Diagnostics comprises Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics. Roche develops medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience, and offers products for researchers in cell analysis, gene expression, genome sequencing, and nucleic acid purification.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy